A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease

Table 1 Patient baseline characteristics n (%)

	Group A(n= 44)	Group B(n= 39)	Pvalue
Age (mean ± SD) (yr)	45.4 ± 15.2	45.1 ± 15.3	0.916
Gender M:F	16:28	16:23	0.663
Duration of symptoms (yr)	4.68 ± 7.79	3.85 ± 4.21	0.552
Esophageal manifestations	28 (63.6)	29 (74.4)	0.293
Regurgitation and heartburn	21 (47.7)	23 (59.0)	0.306
Epigastric pain	8 (18.2)	9 (23.1)	0.581
Nausea	7 (15.9)	6 (15.4)	0.948
Vomiting	0 (0)	1 (2.6)	0.285
Extra-esophageal manifestations	38 (86.4)	33 (84.6)	0.821
Chest pain	16 (36.4)	10 (25.6)	0.293
Globus	24 (54.5)	16 (41.0)	0.219
Hoarseness	15 (34.1)	10 (25.6)	0.402
Metallic taste	22 (50.0)	16 (41.0)	0.413
Nocturnal cough	17 (38.6)	09 (23.1)	0.127
Dyspnea	21 (47.7)	20 (51.3)	0.746
Sore throat	20 (45.5)	13 (33.3)	0.260
Thick sputum production	24 (54.5)	13 (33.3)	0.052
Mixed symptoms	25 (56.8)	24 (61.5)	0.663

Group A, rabeprazole; Group B, ranitidine. M: Male; F: Female.